KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Income (2016 - 2025)

Historic Operating Income for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$178.0 million.

  • Novavax's Operating Income fell 3283.14% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 20201.25%. This contributed to the annual value of -$248.9 million for FY2024, which is 5605.89% up from last year.
  • Per Novavax's latest filing, its Operating Income stood at -$178.0 million for Q3 2025, which was down 3283.14% from $101.1 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Operating Income peaked at $515.5 million during Q1 2025, and registered a low of -$825.0 million during Q4 2021.
  • For the 5-year period, Novavax's Operating Income averaged around -$142.5 million, with its median value being -$144.8 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 193106.24% in 2021, then skyrocketed by 45594.11% in 2025.
  • Quarter analysis of 5 years shows Novavax's Operating Income stood at -$825.0 million in 2021, then surged by 70.44% to -$243.9 million in 2022, then increased by 24.73% to -$183.6 million in 2023, then rose by 28.59% to -$131.1 million in 2024, then plummeted by 35.81% to -$178.0 million in 2025.
  • Its last three reported values are -$178.0 million in Q3 2025, $101.1 million for Q2 2025, and $515.5 million during Q1 2025.